nodes	percent_of_prediction	percent_of_DWPC	metapath
Fentanyl—prostate cancer—Dexamethasone—multiple sclerosis	0.302	0.5	CpDpCtD
Fentanyl—prostate cancer—Betamethasone—multiple sclerosis	0.302	0.5	CpDpCtD
Fentanyl—ABCB1—Methylprednisolone—multiple sclerosis	0.0219	0.0978	CbGbCtD
Fentanyl—CYP3A4—Fingolimod—multiple sclerosis	0.0204	0.0909	CbGbCtD
Fentanyl—CYP3A7-CYP3A51P—Dexamethasone—multiple sclerosis	0.017	0.0758	CbGbCtD
Fentanyl—CYP3A7—Dexamethasone—multiple sclerosis	0.017	0.0758	CbGbCtD
Fentanyl—ABCB1—Mitoxantrone—multiple sclerosis	0.016	0.0714	CbGbCtD
Fentanyl—ABCB1—Betamethasone—multiple sclerosis	0.0143	0.0636	CbGbCtD
Fentanyl—ABCB1—Prednisolone—multiple sclerosis	0.0141	0.0628	CbGbCtD
Fentanyl—ABCB1—Prednisone—multiple sclerosis	0.0133	0.0593	CbGbCtD
Fentanyl—CYP3A4—Methylprednisolone—multiple sclerosis	0.0131	0.0586	CbGbCtD
Fentanyl—CYP3A5—Dexamethasone—multiple sclerosis	0.0127	0.0568	CbGbCtD
Fentanyl—CYP3A4—Triamcinolone—multiple sclerosis	0.00995	0.0444	CbGbCtD
Fentanyl—CYP3A4—Mitoxantrone—multiple sclerosis	0.00958	0.0428	CbGbCtD
Fentanyl—CYP3A4—Betamethasone—multiple sclerosis	0.00854	0.0381	CbGbCtD
Fentanyl—CYP3A4—Prednisolone—multiple sclerosis	0.00843	0.0376	CbGbCtD
Fentanyl—ABCB1—Dexamethasone—multiple sclerosis	0.00829	0.037	CbGbCtD
Fentanyl—CYP3A4—Prednisone—multiple sclerosis	0.00796	0.0355	CbGbCtD
Fentanyl—ABCB1—Methotrexate—multiple sclerosis	0.00666	0.0297	CbGbCtD
Fentanyl—CYP3A4—Dexamethasone—multiple sclerosis	0.00497	0.0222	CbGbCtD
Fentanyl—Quinapril—SLC15A2—multiple sclerosis	0.000689	0.286	CrCbGaD
Fentanyl—Benazepril—SLC15A2—multiple sclerosis	0.000599	0.249	CrCbGaD
Fentanyl—Loperamide—POMC—multiple sclerosis	0.000552	0.229	CrCbGaD
Fentanyl—Trimethaphan—BCHE—multiple sclerosis	0.000374	0.155	CrCbGaD
Fentanyl—Alfentanil—ALB—multiple sclerosis	0.000196	0.0812	CrCbGaD
Fentanyl—Mental disorder—Prednisone—multiple sclerosis	5.33e-05	0.000395	CcSEcCtD
Fentanyl—Nausea—Azathioprine—multiple sclerosis	5.33e-05	0.000394	CcSEcCtD
Fentanyl—Tachycardia—Methylprednisolone—multiple sclerosis	5.33e-05	0.000394	CcSEcCtD
Fentanyl—Skin disorder—Methylprednisolone—multiple sclerosis	5.3e-05	0.000392	CcSEcCtD
Fentanyl—Erythema—Prednisone—multiple sclerosis	5.29e-05	0.000392	CcSEcCtD
Fentanyl—Malnutrition—Prednisone—multiple sclerosis	5.29e-05	0.000392	CcSEcCtD
Fentanyl—Hyperhidrosis—Triamcinolone—multiple sclerosis	5.29e-05	0.000391	CcSEcCtD
Fentanyl—Hyperhidrosis—Methylprednisolone—multiple sclerosis	5.28e-05	0.000391	CcSEcCtD
Fentanyl—Convulsion—Dexamethasone—multiple sclerosis	5.27e-05	0.00039	CcSEcCtD
Fentanyl—Convulsion—Betamethasone—multiple sclerosis	5.27e-05	0.00039	CcSEcCtD
Fentanyl—Hypertension—Dexamethasone—multiple sclerosis	5.25e-05	0.000389	CcSEcCtD
Fentanyl—Hypertension—Betamethasone—multiple sclerosis	5.25e-05	0.000389	CcSEcCtD
Fentanyl—Asthenia—Mitoxantrone—multiple sclerosis	5.2e-05	0.000385	CcSEcCtD
Fentanyl—Myalgia—Dexamethasone—multiple sclerosis	5.18e-05	0.000383	CcSEcCtD
Fentanyl—Myalgia—Betamethasone—multiple sclerosis	5.18e-05	0.000383	CcSEcCtD
Fentanyl—Anxiety—Betamethasone—multiple sclerosis	5.16e-05	0.000382	CcSEcCtD
Fentanyl—Anxiety—Dexamethasone—multiple sclerosis	5.16e-05	0.000382	CcSEcCtD
Fentanyl—Discomfort—Dexamethasone—multiple sclerosis	5.11e-05	0.000379	CcSEcCtD
Fentanyl—Discomfort—Betamethasone—multiple sclerosis	5.11e-05	0.000379	CcSEcCtD
Fentanyl—Haemoglobin—Methotrexate—multiple sclerosis	5.11e-05	0.000378	CcSEcCtD
Fentanyl—Hypotension—Methylprednisolone—multiple sclerosis	5.1e-05	0.000378	CcSEcCtD
Fentanyl—Pain—Prednisolone—multiple sclerosis	5.09e-05	0.000377	CcSEcCtD
Fentanyl—Haemorrhage—Methotrexate—multiple sclerosis	5.08e-05	0.000376	CcSEcCtD
Fentanyl—Pharyngitis—Methotrexate—multiple sclerosis	5.05e-05	0.000374	CcSEcCtD
Fentanyl—Urinary tract disorder—Methotrexate—multiple sclerosis	5.02e-05	0.000372	CcSEcCtD
Fentanyl—Vision blurred—Prednisone—multiple sclerosis	4.99e-05	0.000369	CcSEcCtD
Fentanyl—Urethral disorder—Methotrexate—multiple sclerosis	4.98e-05	0.000369	CcSEcCtD
Fentanyl—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	4.98e-05	0.000369	CcSEcCtD
Fentanyl—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	4.97e-05	0.000368	CcSEcCtD
Fentanyl—Anaphylactic shock—Dexamethasone—multiple sclerosis	4.96e-05	0.000367	CcSEcCtD
Fentanyl—Anaphylactic shock—Betamethasone—multiple sclerosis	4.96e-05	0.000367	CcSEcCtD
Fentanyl—Oedema—Betamethasone—multiple sclerosis	4.96e-05	0.000367	CcSEcCtD
Fentanyl—Oedema—Dexamethasone—multiple sclerosis	4.96e-05	0.000367	CcSEcCtD
Fentanyl—Diarrhoea—Mitoxantrone—multiple sclerosis	4.96e-05	0.000367	CcSEcCtD
Fentanyl—Insomnia—Triamcinolone—multiple sclerosis	4.95e-05	0.000366	CcSEcCtD
Fentanyl—Insomnia—Methylprednisolone—multiple sclerosis	4.94e-05	0.000365	CcSEcCtD
Fentanyl—Infection—Betamethasone—multiple sclerosis	4.93e-05	0.000365	CcSEcCtD
Fentanyl—Infection—Dexamethasone—multiple sclerosis	4.93e-05	0.000365	CcSEcCtD
Fentanyl—Ill-defined disorder—Prednisone—multiple sclerosis	4.91e-05	0.000364	CcSEcCtD
Fentanyl—Paraesthesia—Triamcinolone—multiple sclerosis	4.91e-05	0.000364	CcSEcCtD
Fentanyl—Feeling abnormal—Prednisolone—multiple sclerosis	4.9e-05	0.000363	CcSEcCtD
Fentanyl—Paraesthesia—Methylprednisolone—multiple sclerosis	4.9e-05	0.000363	CcSEcCtD
Fentanyl—Visual impairment—Methotrexate—multiple sclerosis	4.9e-05	0.000363	CcSEcCtD
Fentanyl—Anaemia—Prednisone—multiple sclerosis	4.89e-05	0.000362	CcSEcCtD
Fentanyl—Shock—Dexamethasone—multiple sclerosis	4.88e-05	0.000361	CcSEcCtD
Fentanyl—Shock—Betamethasone—multiple sclerosis	4.88e-05	0.000361	CcSEcCtD
Fentanyl—Dyspnoea—Triamcinolone—multiple sclerosis	4.88e-05	0.000361	CcSEcCtD
Fentanyl—Nervous system disorder—Betamethasone—multiple sclerosis	4.87e-05	0.00036	CcSEcCtD
Fentanyl—Nervous system disorder—Dexamethasone—multiple sclerosis	4.87e-05	0.00036	CcSEcCtD
Fentanyl—Agitation—Prednisone—multiple sclerosis	4.87e-05	0.00036	CcSEcCtD
Fentanyl—Thrombocytopenia—Dexamethasone—multiple sclerosis	4.86e-05	0.00036	CcSEcCtD
Fentanyl—Thrombocytopenia—Betamethasone—multiple sclerosis	4.86e-05	0.00036	CcSEcCtD
Fentanyl—Tachycardia—Dexamethasone—multiple sclerosis	4.84e-05	0.000359	CcSEcCtD
Fentanyl—Tachycardia—Betamethasone—multiple sclerosis	4.84e-05	0.000359	CcSEcCtD
Fentanyl—Dyspepsia—Triamcinolone—multiple sclerosis	4.81e-05	0.000356	CcSEcCtD
Fentanyl—Erythema multiforme—Methotrexate—multiple sclerosis	4.81e-05	0.000356	CcSEcCtD
Fentanyl—Dyspepsia—Methylprednisolone—multiple sclerosis	4.8e-05	0.000356	CcSEcCtD
Fentanyl—Hyperhidrosis—Betamethasone—multiple sclerosis	4.8e-05	0.000355	CcSEcCtD
Fentanyl—Hyperhidrosis—Dexamethasone—multiple sclerosis	4.8e-05	0.000355	CcSEcCtD
Fentanyl—Malaise—Prednisone—multiple sclerosis	4.77e-05	0.000354	CcSEcCtD
Fentanyl—Vertigo—Prednisone—multiple sclerosis	4.76e-05	0.000352	CcSEcCtD
Fentanyl—Eye disorder—Methotrexate—multiple sclerosis	4.75e-05	0.000352	CcSEcCtD
Fentanyl—Syncope—Prednisone—multiple sclerosis	4.75e-05	0.000352	CcSEcCtD
Fentanyl—Tinnitus—Methotrexate—multiple sclerosis	4.74e-05	0.000351	CcSEcCtD
Fentanyl—Anorexia—Dexamethasone—multiple sclerosis	4.73e-05	0.00035	CcSEcCtD
Fentanyl—Anorexia—Betamethasone—multiple sclerosis	4.73e-05	0.00035	CcSEcCtD
Fentanyl—Urticaria—Prednisolone—multiple sclerosis	4.72e-05	0.00035	CcSEcCtD
Fentanyl—Cardiac disorder—Methotrexate—multiple sclerosis	4.72e-05	0.000349	CcSEcCtD
Fentanyl—Fatigue—Triamcinolone—multiple sclerosis	4.72e-05	0.000349	CcSEcCtD
Fentanyl—Fatigue—Methylprednisolone—multiple sclerosis	4.7e-05	0.000348	CcSEcCtD
Fentanyl—Pain—Triamcinolone—multiple sclerosis	4.68e-05	0.000346	CcSEcCtD
Fentanyl—Loss of consciousness—Prednisone—multiple sclerosis	4.65e-05	0.000345	CcSEcCtD
Fentanyl—Hypotension—Betamethasone—multiple sclerosis	4.64e-05	0.000343	CcSEcCtD
Fentanyl—Hypotension—Dexamethasone—multiple sclerosis	4.64e-05	0.000343	CcSEcCtD
Fentanyl—Angiopathy—Methotrexate—multiple sclerosis	4.61e-05	0.000341	CcSEcCtD
Fentanyl—Vomiting—Mitoxantrone—multiple sclerosis	4.61e-05	0.000341	CcSEcCtD
Fentanyl—Immune system disorder—Methotrexate—multiple sclerosis	4.59e-05	0.00034	CcSEcCtD
Fentanyl—Convulsion—Prednisone—multiple sclerosis	4.59e-05	0.00034	CcSEcCtD
Fentanyl—Mediastinal disorder—Methotrexate—multiple sclerosis	4.58e-05	0.000339	CcSEcCtD
Fentanyl—Hypertension—Prednisone—multiple sclerosis	4.57e-05	0.000338	CcSEcCtD
Fentanyl—Rash—Mitoxantrone—multiple sclerosis	4.57e-05	0.000338	CcSEcCtD
Fentanyl—Dermatitis—Mitoxantrone—multiple sclerosis	4.57e-05	0.000338	CcSEcCtD
Fentanyl—Chills—Methotrexate—multiple sclerosis	4.56e-05	0.000338	CcSEcCtD
Fentanyl—Headache—Mitoxantrone—multiple sclerosis	4.54e-05	0.000336	CcSEcCtD
Fentanyl—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	4.52e-05	0.000335	CcSEcCtD
Fentanyl—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	4.52e-05	0.000335	CcSEcCtD
Fentanyl—Myalgia—Prednisone—multiple sclerosis	4.51e-05	0.000334	CcSEcCtD
Fentanyl—Arthralgia—Prednisone—multiple sclerosis	4.51e-05	0.000334	CcSEcCtD
Fentanyl—Feeling abnormal—Triamcinolone—multiple sclerosis	4.51e-05	0.000334	CcSEcCtD
Fentanyl—Feeling abnormal—Methylprednisolone—multiple sclerosis	4.5e-05	0.000333	CcSEcCtD
Fentanyl—Anxiety—Prednisone—multiple sclerosis	4.49e-05	0.000333	CcSEcCtD
Fentanyl—Alopecia—Methotrexate—multiple sclerosis	4.49e-05	0.000333	CcSEcCtD
Fentanyl—Insomnia—Dexamethasone—multiple sclerosis	4.49e-05	0.000332	CcSEcCtD
Fentanyl—Insomnia—Betamethasone—multiple sclerosis	4.49e-05	0.000332	CcSEcCtD
Fentanyl—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	4.48e-05	0.000331	CcSEcCtD
Fentanyl—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	4.46e-05	0.00033	CcSEcCtD
Fentanyl—Paraesthesia—Dexamethasone—multiple sclerosis	4.46e-05	0.00033	CcSEcCtD
Fentanyl—Paraesthesia—Betamethasone—multiple sclerosis	4.46e-05	0.00033	CcSEcCtD
Fentanyl—Discomfort—Prednisone—multiple sclerosis	4.45e-05	0.00033	CcSEcCtD
Fentanyl—Mental disorder—Methotrexate—multiple sclerosis	4.45e-05	0.00033	CcSEcCtD
Fentanyl—Malnutrition—Methotrexate—multiple sclerosis	4.43e-05	0.000328	CcSEcCtD
Fentanyl—Erythema—Methotrexate—multiple sclerosis	4.43e-05	0.000328	CcSEcCtD
Fentanyl—Hypersensitivity—Prednisolone—multiple sclerosis	4.38e-05	0.000324	CcSEcCtD
Fentanyl—Dyspepsia—Dexamethasone—multiple sclerosis	4.37e-05	0.000323	CcSEcCtD
Fentanyl—Dyspepsia—Betamethasone—multiple sclerosis	4.37e-05	0.000323	CcSEcCtD
Fentanyl—Urticaria—Triamcinolone—multiple sclerosis	4.34e-05	0.000322	CcSEcCtD
Fentanyl—Urticaria—Methylprednisolone—multiple sclerosis	4.33e-05	0.000321	CcSEcCtD
Fentanyl—Dysgeusia—Methotrexate—multiple sclerosis	4.33e-05	0.000321	CcSEcCtD
Fentanyl—Body temperature increased—Triamcinolone—multiple sclerosis	4.32e-05	0.00032	CcSEcCtD
Fentanyl—Anaphylactic shock—Prednisone—multiple sclerosis	4.32e-05	0.00032	CcSEcCtD
Fentanyl—Oedema—Prednisone—multiple sclerosis	4.32e-05	0.00032	CcSEcCtD
Fentanyl—Abdominal pain—Methylprednisolone—multiple sclerosis	4.31e-05	0.000319	CcSEcCtD
Fentanyl—Decreased appetite—Dexamethasone—multiple sclerosis	4.31e-05	0.000319	CcSEcCtD
Fentanyl—Decreased appetite—Betamethasone—multiple sclerosis	4.31e-05	0.000319	CcSEcCtD
Fentanyl—Nausea—Mitoxantrone—multiple sclerosis	4.31e-05	0.000319	CcSEcCtD
Fentanyl—Infection—Prednisone—multiple sclerosis	4.29e-05	0.000318	CcSEcCtD
Fentanyl—Gastrointestinal disorder—Betamethasone—multiple sclerosis	4.28e-05	0.000317	CcSEcCtD
Fentanyl—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	4.28e-05	0.000317	CcSEcCtD
Fentanyl—Back pain—Methotrexate—multiple sclerosis	4.28e-05	0.000317	CcSEcCtD
Fentanyl—Fatigue—Dexamethasone—multiple sclerosis	4.28e-05	0.000317	CcSEcCtD
Fentanyl—Fatigue—Betamethasone—multiple sclerosis	4.28e-05	0.000317	CcSEcCtD
Fentanyl—Shock—Prednisone—multiple sclerosis	4.25e-05	0.000315	CcSEcCtD
Fentanyl—Pain—Dexamethasone—multiple sclerosis	4.24e-05	0.000314	CcSEcCtD
Fentanyl—Pain—Betamethasone—multiple sclerosis	4.24e-05	0.000314	CcSEcCtD
Fentanyl—Nervous system disorder—Prednisone—multiple sclerosis	4.24e-05	0.000314	CcSEcCtD
Fentanyl—Tachycardia—Prednisone—multiple sclerosis	4.22e-05	0.000312	CcSEcCtD
Fentanyl—Skin disorder—Prednisone—multiple sclerosis	4.2e-05	0.000311	CcSEcCtD
Fentanyl—Hyperhidrosis—Prednisone—multiple sclerosis	4.18e-05	0.000309	CcSEcCtD
Fentanyl—Vision blurred—Methotrexate—multiple sclerosis	4.17e-05	0.000309	CcSEcCtD
Fentanyl—Anorexia—Prednisone—multiple sclerosis	4.12e-05	0.000305	CcSEcCtD
Fentanyl—Ill-defined disorder—Methotrexate—multiple sclerosis	4.11e-05	0.000304	CcSEcCtD
Fentanyl—Anaemia—Methotrexate—multiple sclerosis	4.09e-05	0.000303	CcSEcCtD
Fentanyl—Feeling abnormal—Dexamethasone—multiple sclerosis	4.09e-05	0.000303	CcSEcCtD
Fentanyl—Feeling abnormal—Betamethasone—multiple sclerosis	4.09e-05	0.000303	CcSEcCtD
Fentanyl—Gastrointestinal pain—Dexamethasone—multiple sclerosis	4.06e-05	0.0003	CcSEcCtD
Fentanyl—Gastrointestinal pain—Betamethasone—multiple sclerosis	4.06e-05	0.0003	CcSEcCtD
Fentanyl—Hypersensitivity—Triamcinolone—multiple sclerosis	4.03e-05	0.000298	CcSEcCtD
Fentanyl—Hypersensitivity—Methylprednisolone—multiple sclerosis	4.02e-05	0.000298	CcSEcCtD
Fentanyl—Malaise—Methotrexate—multiple sclerosis	3.99e-05	0.000295	CcSEcCtD
Fentanyl—Vertigo—Methotrexate—multiple sclerosis	3.98e-05	0.000294	CcSEcCtD
Fentanyl—Leukopenia—Methotrexate—multiple sclerosis	3.96e-05	0.000293	CcSEcCtD
Fentanyl—Urticaria—Dexamethasone—multiple sclerosis	3.94e-05	0.000292	CcSEcCtD
Fentanyl—Urticaria—Betamethasone—multiple sclerosis	3.94e-05	0.000292	CcSEcCtD
Fentanyl—Musculoskeletal discomfort—Prednisone—multiple sclerosis	3.94e-05	0.000292	CcSEcCtD
Fentanyl—Dizziness—Prednisolone—multiple sclerosis	3.93e-05	0.000291	CcSEcCtD
Fentanyl—Asthenia—Triamcinolone—multiple sclerosis	3.92e-05	0.000291	CcSEcCtD
Fentanyl—Abdominal pain—Betamethasone—multiple sclerosis	3.92e-05	0.00029	CcSEcCtD
Fentanyl—Body temperature increased—Betamethasone—multiple sclerosis	3.92e-05	0.00029	CcSEcCtD
Fentanyl—Body temperature increased—Dexamethasone—multiple sclerosis	3.92e-05	0.00029	CcSEcCtD
Fentanyl—Abdominal pain—Dexamethasone—multiple sclerosis	3.92e-05	0.00029	CcSEcCtD
Fentanyl—Asthenia—Methylprednisolone—multiple sclerosis	3.92e-05	0.00029	CcSEcCtD
Fentanyl—Insomnia—Prednisone—multiple sclerosis	3.91e-05	0.000289	CcSEcCtD
Fentanyl—Paraesthesia—Prednisone—multiple sclerosis	3.88e-05	0.000287	CcSEcCtD
Fentanyl—Pruritus—Triamcinolone—multiple sclerosis	3.87e-05	0.000286	CcSEcCtD
Fentanyl—Cough—Methotrexate—multiple sclerosis	3.86e-05	0.000286	CcSEcCtD
Fentanyl—Pruritus—Methylprednisolone—multiple sclerosis	3.86e-05	0.000286	CcSEcCtD
Fentanyl—Convulsion—Methotrexate—multiple sclerosis	3.83e-05	0.000284	CcSEcCtD
Fentanyl—Dyspepsia—Prednisone—multiple sclerosis	3.8e-05	0.000282	CcSEcCtD
Fentanyl—Chest pain—Methotrexate—multiple sclerosis	3.77e-05	0.000279	CcSEcCtD
Fentanyl—Arthralgia—Methotrexate—multiple sclerosis	3.77e-05	0.000279	CcSEcCtD
Fentanyl—Myalgia—Methotrexate—multiple sclerosis	3.77e-05	0.000279	CcSEcCtD
Fentanyl—Decreased appetite—Prednisone—multiple sclerosis	3.76e-05	0.000278	CcSEcCtD
Fentanyl—Rash—Prednisolone—multiple sclerosis	3.75e-05	0.000278	CcSEcCtD
Fentanyl—Dermatitis—Prednisolone—multiple sclerosis	3.75e-05	0.000277	CcSEcCtD
Fentanyl—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	3.74e-05	0.000277	CcSEcCtD
Fentanyl—Diarrhoea—Methylprednisolone—multiple sclerosis	3.73e-05	0.000276	CcSEcCtD
Fentanyl—Fatigue—Prednisone—multiple sclerosis	3.73e-05	0.000276	CcSEcCtD
Fentanyl—Headache—Prednisolone—multiple sclerosis	3.73e-05	0.000276	CcSEcCtD
Fentanyl—Discomfort—Methotrexate—multiple sclerosis	3.72e-05	0.000276	CcSEcCtD
Fentanyl—Constipation—Prednisone—multiple sclerosis	3.7e-05	0.000274	CcSEcCtD
Fentanyl—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	3.67e-05	0.00107	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—GPR65—multiple sclerosis	3.66e-05	0.00107	CbGpPWpGaD
Fentanyl—OPRD1—GPCR ligand binding—CCR5—multiple sclerosis	3.66e-05	0.00107	CbGpPWpGaD
Fentanyl—Confusional state—Methotrexate—multiple sclerosis	3.64e-05	0.00027	CcSEcCtD
Fentanyl—OPRK1—Signaling Pathways—TAGAP—multiple sclerosis	3.64e-05	0.00106	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—S1PR1—multiple sclerosis	3.62e-05	0.00106	CbGpPWpGaD
Fentanyl—Dizziness—Triamcinolone—multiple sclerosis	3.62e-05	0.000268	CcSEcCtD
Fentanyl—Anaphylactic shock—Methotrexate—multiple sclerosis	3.61e-05	0.000267	CcSEcCtD
Fentanyl—Dizziness—Methylprednisolone—multiple sclerosis	3.61e-05	0.000267	CcSEcCtD
Fentanyl—Infection—Methotrexate—multiple sclerosis	3.59e-05	0.000266	CcSEcCtD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	3.58e-05	0.00104	CbGpPWpGaD
Fentanyl—OPRK1—GPCR ligand binding—CCL5—multiple sclerosis	3.56e-05	0.00104	CbGpPWpGaD
Fentanyl—Feeling abnormal—Prednisone—multiple sclerosis	3.56e-05	0.000264	CcSEcCtD
Fentanyl—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	3.56e-05	0.00104	CbGpPWpGaD
Fentanyl—Asthenia—Betamethasone—multiple sclerosis	3.56e-05	0.000264	CcSEcCtD
Fentanyl—Asthenia—Dexamethasone—multiple sclerosis	3.56e-05	0.000264	CcSEcCtD
Fentanyl—OPRM1—Signaling Pathways—LINGO1—multiple sclerosis	3.54e-05	0.00103	CbGpPWpGaD
Fentanyl—Nervous system disorder—Methotrexate—multiple sclerosis	3.54e-05	0.000262	CcSEcCtD
Fentanyl—Thrombocytopenia—Methotrexate—multiple sclerosis	3.54e-05	0.000262	CcSEcCtD
Fentanyl—Gastrointestinal pain—Prednisone—multiple sclerosis	3.53e-05	0.000262	CcSEcCtD
Fentanyl—Nausea—Prednisolone—multiple sclerosis	3.53e-05	0.000262	CcSEcCtD
Fentanyl—OPRD1—Signaling Pathways—GPC5—multiple sclerosis	3.52e-05	0.00103	CbGpPWpGaD
Fentanyl—Pruritus—Dexamethasone—multiple sclerosis	3.51e-05	0.00026	CcSEcCtD
Fentanyl—Pruritus—Betamethasone—multiple sclerosis	3.51e-05	0.00026	CcSEcCtD
Fentanyl—Skin disorder—Methotrexate—multiple sclerosis	3.51e-05	0.00026	CcSEcCtD
Fentanyl—OPRM1—G alpha (i) signalling events—POMC—multiple sclerosis	3.5e-05	0.00102	CbGpPWpGaD
Fentanyl—OPRM1—GPCR ligand binding—CXCL10—multiple sclerosis	3.5e-05	0.00102	CbGpPWpGaD
Fentanyl—Hyperhidrosis—Methotrexate—multiple sclerosis	3.49e-05	0.000259	CcSEcCtD
Fentanyl—Vomiting—Triamcinolone—multiple sclerosis	3.48e-05	0.000257	CcSEcCtD
Fentanyl—Vomiting—Methylprednisolone—multiple sclerosis	3.47e-05	0.000257	CcSEcCtD
Fentanyl—Rash—Triamcinolone—multiple sclerosis	3.45e-05	0.000255	CcSEcCtD
Fentanyl—Dermatitis—Triamcinolone—multiple sclerosis	3.45e-05	0.000255	CcSEcCtD
Fentanyl—Anorexia—Methotrexate—multiple sclerosis	3.44e-05	0.000255	CcSEcCtD
Fentanyl—Rash—Methylprednisolone—multiple sclerosis	3.44e-05	0.000255	CcSEcCtD
Fentanyl—Dermatitis—Methylprednisolone—multiple sclerosis	3.44e-05	0.000255	CcSEcCtD
Fentanyl—Urticaria—Prednisone—multiple sclerosis	3.43e-05	0.000254	CcSEcCtD
Fentanyl—Headache—Triamcinolone—multiple sclerosis	3.43e-05	0.000254	CcSEcCtD
Fentanyl—Headache—Methylprednisolone—multiple sclerosis	3.42e-05	0.000253	CcSEcCtD
Fentanyl—Abdominal pain—Prednisone—multiple sclerosis	3.42e-05	0.000253	CcSEcCtD
Fentanyl—Body temperature increased—Prednisone—multiple sclerosis	3.42e-05	0.000253	CcSEcCtD
Fentanyl—OPRD1—GPCR downstream signaling—PTGER4—multiple sclerosis	3.42e-05	0.000996	CbGpPWpGaD
Fentanyl—Diarrhoea—Betamethasone—multiple sclerosis	3.4e-05	0.000251	CcSEcCtD
Fentanyl—Diarrhoea—Dexamethasone—multiple sclerosis	3.4e-05	0.000251	CcSEcCtD
Fentanyl—Hypotension—Methotrexate—multiple sclerosis	3.37e-05	0.00025	CcSEcCtD
Fentanyl—OPRM1—Signaling by GPCR—CXCL13—multiple sclerosis	3.35e-05	0.000977	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—CCR1—multiple sclerosis	3.35e-05	0.000977	CbGpPWpGaD
Fentanyl—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—multiple sclerosis	3.33e-05	0.00097	CbGpPWpGaD
Fentanyl—OPRD1—GPCR downstream signaling—CXCR3—multiple sclerosis	3.3e-05	0.000962	CbGpPWpGaD
Fentanyl—OPRK1—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	3.29e-05	0.00096	CbGpPWpGaD
Fentanyl—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	3.29e-05	0.000244	CcSEcCtD
Fentanyl—Dizziness—Dexamethasone—multiple sclerosis	3.28e-05	0.000243	CcSEcCtD
Fentanyl—Dizziness—Betamethasone—multiple sclerosis	3.28e-05	0.000243	CcSEcCtD
Fentanyl—OPRM1—TCR Signaling Pathway—IL6—multiple sclerosis	3.28e-05	0.000956	CbGpPWpGaD
Fentanyl—ABCB1—Allograft Rejection—IFNG—multiple sclerosis	3.27e-05	0.000953	CbGpPWpGaD
Fentanyl—Insomnia—Methotrexate—multiple sclerosis	3.27e-05	0.000242	CcSEcCtD
Fentanyl—Nausea—Triamcinolone—multiple sclerosis	3.25e-05	0.000241	CcSEcCtD
Fentanyl—Paraesthesia—Methotrexate—multiple sclerosis	3.24e-05	0.00024	CcSEcCtD
Fentanyl—Nausea—Methylprednisolone—multiple sclerosis	3.24e-05	0.00024	CcSEcCtD
Fentanyl—OPRD1—Signaling by GPCR—CCL3—multiple sclerosis	3.22e-05	0.00094	CbGpPWpGaD
Fentanyl—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	3.22e-05	0.000939	CbGpPWpGaD
Fentanyl—Dyspnoea—Methotrexate—multiple sclerosis	3.22e-05	0.000238	CcSEcCtD
Fentanyl—Somnolence—Methotrexate—multiple sclerosis	3.21e-05	0.000238	CcSEcCtD
Fentanyl—OPRD1—GPCR downstream signaling—CCR2—multiple sclerosis	3.21e-05	0.000936	CbGpPWpGaD
Fentanyl—OPRK1—GPCR ligand binding—CCR5—multiple sclerosis	3.21e-05	0.000936	CbGpPWpGaD
Fentanyl—Hypersensitivity—Prednisone—multiple sclerosis	3.18e-05	0.000236	CcSEcCtD
Fentanyl—Dyspepsia—Methotrexate—multiple sclerosis	3.18e-05	0.000235	CcSEcCtD
Fentanyl—OPRK1—Signaling Pathways—S1PR1—multiple sclerosis	3.18e-05	0.000926	CbGpPWpGaD
Fentanyl—Vomiting—Betamethasone—multiple sclerosis	3.16e-05	0.000234	CcSEcCtD
Fentanyl—Vomiting—Dexamethasone—multiple sclerosis	3.16e-05	0.000234	CcSEcCtD
Fentanyl—Decreased appetite—Methotrexate—multiple sclerosis	3.14e-05	0.000232	CcSEcCtD
Fentanyl—Rash—Dexamethasone—multiple sclerosis	3.13e-05	0.000232	CcSEcCtD
Fentanyl—Rash—Betamethasone—multiple sclerosis	3.13e-05	0.000232	CcSEcCtD
Fentanyl—Dermatitis—Dexamethasone—multiple sclerosis	3.13e-05	0.000231	CcSEcCtD
Fentanyl—Dermatitis—Betamethasone—multiple sclerosis	3.13e-05	0.000231	CcSEcCtD
Fentanyl—Gastrointestinal disorder—Methotrexate—multiple sclerosis	3.12e-05	0.000231	CcSEcCtD
Fentanyl—Fatigue—Methotrexate—multiple sclerosis	3.11e-05	0.000231	CcSEcCtD
Fentanyl—Headache—Dexamethasone—multiple sclerosis	3.11e-05	0.00023	CcSEcCtD
Fentanyl—Headache—Betamethasone—multiple sclerosis	3.11e-05	0.00023	CcSEcCtD
Fentanyl—OPRD1—Signaling by GPCR—PTGER4—multiple sclerosis	3.1e-05	0.000904	CbGpPWpGaD
Fentanyl—Asthenia—Prednisone—multiple sclerosis	3.1e-05	0.00023	CcSEcCtD
Fentanyl—OPRK1—Signaling Pathways—GPC5—multiple sclerosis	3.09e-05	0.000901	CbGpPWpGaD
Fentanyl—Pain—Methotrexate—multiple sclerosis	3.09e-05	0.000229	CcSEcCtD
Fentanyl—OPRD1—Signaling Pathways—RGS1—multiple sclerosis	3.08e-05	0.000898	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—TAGAP—multiple sclerosis	3.07e-05	0.000896	CbGpPWpGaD
Fentanyl—Pruritus—Prednisone—multiple sclerosis	3.06e-05	0.000226	CcSEcCtD
Fentanyl—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	3.02e-05	0.000879	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—SRM—multiple sclerosis	3.01e-05	0.000879	CbGpPWpGaD
Fentanyl—OPRM1—GPCR ligand binding—CCL5—multiple sclerosis	3.01e-05	0.000878	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—CXCR3—multiple sclerosis	3e-05	0.000873	CbGpPWpGaD
Fentanyl—OPRK1—GPCR downstream signaling—PTGER4—multiple sclerosis	2.99e-05	0.000873	CbGpPWpGaD
Fentanyl—Feeling abnormal—Methotrexate—multiple sclerosis	2.98e-05	0.00022	CcSEcCtD
Fentanyl—OPRD1—GPCR downstream signaling—CNR1—multiple sclerosis	2.96e-05	0.000864	CbGpPWpGaD
Fentanyl—Diarrhoea—Prednisone—multiple sclerosis	2.96e-05	0.000219	CcSEcCtD
Fentanyl—Gastrointestinal pain—Methotrexate—multiple sclerosis	2.95e-05	0.000219	CcSEcCtD
Fentanyl—Nausea—Betamethasone—multiple sclerosis	2.95e-05	0.000218	CcSEcCtD
Fentanyl—Nausea—Dexamethasone—multiple sclerosis	2.95e-05	0.000218	CcSEcCtD
Fentanyl—CYP3A7—Metabolism—CYP24A1—multiple sclerosis	2.94e-05	0.000857	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—CYP27B1—multiple sclerosis	2.94e-05	0.000857	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—GPR65—multiple sclerosis	2.92e-05	0.000852	CbGpPWpGaD
Fentanyl—ABCB1—Allograft Rejection—IL1B—multiple sclerosis	2.91e-05	0.00085	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—CCR2—multiple sclerosis	2.91e-05	0.00085	CbGpPWpGaD
Fentanyl—ABCB1—Allograft Rejection—IL2—multiple sclerosis	2.9e-05	0.000847	CbGpPWpGaD
Fentanyl—OPRK1—GPCR downstream signaling—CXCR3—multiple sclerosis	2.89e-05	0.000843	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	2.87e-05	0.000838	CbGpPWpGaD
Fentanyl—Urticaria—Methotrexate—multiple sclerosis	2.87e-05	0.000212	CcSEcCtD
Fentanyl—OPRD1—GPCR ligand binding—POMC—multiple sclerosis	2.86e-05	0.000834	CbGpPWpGaD
Fentanyl—Dizziness—Prednisone—multiple sclerosis	2.86e-05	0.000212	CcSEcCtD
Fentanyl—Body temperature increased—Methotrexate—multiple sclerosis	2.85e-05	0.000211	CcSEcCtD
Fentanyl—Abdominal pain—Methotrexate—multiple sclerosis	2.85e-05	0.000211	CcSEcCtD
Fentanyl—OPRK1—Signaling by GPCR—CCL3—multiple sclerosis	2.83e-05	0.000824	CbGpPWpGaD
Fentanyl—OPRK1—GPCR downstream signaling—CCR2—multiple sclerosis	2.81e-05	0.00082	CbGpPWpGaD
Fentanyl—OPRD1—GPCR ligand binding—CCL2—multiple sclerosis	2.8e-05	0.000816	CbGpPWpGaD
Fentanyl—CYP3A5—Biological oxidations—POMC—multiple sclerosis	2.79e-05	0.000814	CbGpPWpGaD
Fentanyl—ABCB1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	2.79e-05	0.000813	CbGpPWpGaD
Fentanyl—OPRM1—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	2.78e-05	0.000812	CbGpPWpGaD
Fentanyl—Vomiting—Prednisone—multiple sclerosis	2.75e-05	0.000203	CcSEcCtD
Fentanyl—Rash—Prednisone—multiple sclerosis	2.72e-05	0.000202	CcSEcCtD
Fentanyl—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	2.72e-05	0.000794	CbGpPWpGaD
Fentanyl—Dermatitis—Prednisone—multiple sclerosis	2.72e-05	0.000202	CcSEcCtD
Fentanyl—OPRK1—Signaling by GPCR—PTGER4—multiple sclerosis	2.72e-05	0.000793	CbGpPWpGaD
Fentanyl—OPRM1—GPCR ligand binding—CCR5—multiple sclerosis	2.71e-05	0.000791	CbGpPWpGaD
Fentanyl—Headache—Prednisone—multiple sclerosis	2.71e-05	0.0002	CcSEcCtD
Fentanyl—OPRK1—Signaling Pathways—RGS1—multiple sclerosis	2.7e-05	0.000788	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—CNR1—multiple sclerosis	2.69e-05	0.000784	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—GPC5—multiple sclerosis	2.69e-05	0.000783	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—S1PR1—multiple sclerosis	2.69e-05	0.000783	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—CCR1—multiple sclerosis	2.67e-05	0.000779	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—CXCL13—multiple sclerosis	2.67e-05	0.000779	CbGpPWpGaD
Fentanyl—OPRD1—GPCR downstream signaling—CXCL10—multiple sclerosis	2.67e-05	0.000777	CbGpPWpGaD
Fentanyl—Hypersensitivity—Methotrexate—multiple sclerosis	2.66e-05	0.000197	CcSEcCtD
Fentanyl—OPRK1—Signaling by GPCR—CXCR3—multiple sclerosis	2.63e-05	0.000766	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—GPC5—multiple sclerosis	2.61e-05	0.000762	CbGpPWpGaD
Fentanyl—OPRK1—GPCR downstream signaling—CNR1—multiple sclerosis	2.6e-05	0.000757	CbGpPWpGaD
Fentanyl—Asthenia—Methotrexate—multiple sclerosis	2.59e-05	0.000192	CcSEcCtD
Fentanyl—Nausea—Prednisone—multiple sclerosis	2.57e-05	0.00019	CcSEcCtD
Fentanyl—OPRK1—Signaling Pathways—GPR65—multiple sclerosis	2.56e-05	0.000747	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—CCR2—multiple sclerosis	2.56e-05	0.000745	CbGpPWpGaD
Fentanyl—Pruritus—Methotrexate—multiple sclerosis	2.56e-05	0.000189	CcSEcCtD
Fentanyl—OPRM1—GPCR downstream signaling—PTGER4—multiple sclerosis	2.53e-05	0.000738	CbGpPWpGaD
Fentanyl—OPRK1—GPCR ligand binding—POMC—multiple sclerosis	2.51e-05	0.000731	CbGpPWpGaD
Fentanyl—Diarrhoea—Methotrexate—multiple sclerosis	2.47e-05	0.000183	CcSEcCtD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	2.46e-05	0.000717	CbGpPWpGaD
Fentanyl—OPRK1—GPCR ligand binding—CCL2—multiple sclerosis	2.45e-05	0.000715	CbGpPWpGaD
Fentanyl—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	2.44e-05	0.000713	CbGpPWpGaD
Fentanyl—OPRM1—GPCR downstream signaling—CXCR3—multiple sclerosis	2.44e-05	0.000713	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—CXCL10—multiple sclerosis	2.42e-05	0.000706	CbGpPWpGaD
Fentanyl—Dizziness—Methotrexate—multiple sclerosis	2.39e-05	0.000177	CcSEcCtD
Fentanyl—OPRM1—Signaling by GPCR—CCL3—multiple sclerosis	2.39e-05	0.000696	CbGpPWpGaD
Fentanyl—OPRM1—GPCR downstream signaling—CCR2—multiple sclerosis	2.38e-05	0.000693	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—CNR1—multiple sclerosis	2.36e-05	0.000688	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CXCL13—multiple sclerosis	2.34e-05	0.000683	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CCR1—multiple sclerosis	2.34e-05	0.000683	CbGpPWpGaD
Fentanyl—OPRK1—GPCR downstream signaling—CXCL10—multiple sclerosis	2.34e-05	0.000682	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—PTGER4—multiple sclerosis	2.3e-05	0.00067	CbGpPWpGaD
Fentanyl—Vomiting—Methotrexate—multiple sclerosis	2.3e-05	0.00017	CcSEcCtD
Fentanyl—OPRD1—GPCR downstream signaling—CCL5—multiple sclerosis	2.3e-05	0.000669	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—RGS1—multiple sclerosis	2.28e-05	0.000666	CbGpPWpGaD
Fentanyl—Rash—Methotrexate—multiple sclerosis	2.28e-05	0.000169	CcSEcCtD
Fentanyl—Dermatitis—Methotrexate—multiple sclerosis	2.28e-05	0.000168	CcSEcCtD
Fentanyl—ABCB1—Metabolism—SRM—multiple sclerosis	2.27e-05	0.000663	CbGpPWpGaD
Fentanyl—ABCB1—Allograft Rejection—TGFB1—multiple sclerosis	2.26e-05	0.00066	CbGpPWpGaD
Fentanyl—Headache—Methotrexate—multiple sclerosis	2.26e-05	0.000168	CcSEcCtD
Fentanyl—CYP3A7—Metabolism—RRM1—multiple sclerosis	2.23e-05	0.000649	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—CXCR3—multiple sclerosis	2.22e-05	0.000647	CbGpPWpGaD
Fentanyl—ABCB1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	2.2e-05	0.000643	CbGpPWpGaD
Fentanyl—OPRM1—GPCR downstream signaling—CNR1—multiple sclerosis	2.19e-05	0.00064	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—GPR65—multiple sclerosis	2.16e-05	0.000631	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—CCR2—multiple sclerosis	2.16e-05	0.00063	CbGpPWpGaD
Fentanyl—Nausea—Methotrexate—multiple sclerosis	2.15e-05	0.000159	CcSEcCtD
Fentanyl—CYP3A5—Metabolism—CYP27B1—multiple sclerosis	2.12e-05	0.000619	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—CYP24A1—multiple sclerosis	2.12e-05	0.000619	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—CXCL10—multiple sclerosis	2.12e-05	0.000619	CbGpPWpGaD
Fentanyl—OPRM1—GPCR ligand binding—POMC—multiple sclerosis	2.12e-05	0.000618	CbGpPWpGaD
Fentanyl—ABCB1—Allograft Rejection—TNF—multiple sclerosis	2.11e-05	0.000617	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—CCL5—multiple sclerosis	2.08e-05	0.000608	CbGpPWpGaD
Fentanyl—OPRM1—GPCR ligand binding—CCL2—multiple sclerosis	2.07e-05	0.000605	CbGpPWpGaD
Fentanyl—OPRD1—GPCR downstream signaling—CCR5—multiple sclerosis	2.07e-05	0.000603	CbGpPWpGaD
Fentanyl—OPRD1—GPCR downstream signaling—IL2RA—multiple sclerosis	2.04e-05	0.000594	CbGpPWpGaD
Fentanyl—OPRK1—GPCR downstream signaling—CCL5—multiple sclerosis	2.01e-05	0.000587	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—CNR1—multiple sclerosis	1.99e-05	0.000581	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CXCL13—multiple sclerosis	1.98e-05	0.000577	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CCR1—multiple sclerosis	1.98e-05	0.000577	CbGpPWpGaD
Fentanyl—OPRM1—GPCR downstream signaling—CXCL10—multiple sclerosis	1.98e-05	0.000576	CbGpPWpGaD
Fentanyl—ABCB1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	1.95e-05	0.000568	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—GPC5—multiple sclerosis	1.94e-05	0.000566	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—CCL3—multiple sclerosis	1.9e-05	0.000555	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—CCR5—multiple sclerosis	1.88e-05	0.000548	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—IL2RA—multiple sclerosis	1.85e-05	0.00054	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—PTGER4—multiple sclerosis	1.83e-05	0.000534	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—CCL5—multiple sclerosis	1.83e-05	0.000533	CbGpPWpGaD
Fentanyl—OPRK1—GPCR downstream signaling—CCR5—multiple sclerosis	1.81e-05	0.000529	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—PGR—multiple sclerosis	1.8e-05	0.000526	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—CXCL10—multiple sclerosis	1.79e-05	0.000523	CbGpPWpGaD
Fentanyl—OPRK1—GPCR downstream signaling—IL2RA—multiple sclerosis	1.79e-05	0.000521	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—CXCR3—multiple sclerosis	1.77e-05	0.000516	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—CD28—multiple sclerosis	1.75e-05	0.000511	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—CCR2—multiple sclerosis	1.72e-05	0.000502	CbGpPWpGaD
Fentanyl—OPRM1—GPCR downstream signaling—CCL5—multiple sclerosis	1.7e-05	0.000496	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CCL3—multiple sclerosis	1.67e-05	0.000487	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—CCR5—multiple sclerosis	1.65e-05	0.00048	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—IL2RA—multiple sclerosis	1.62e-05	0.000473	CbGpPWpGaD
Fentanyl—OPRD1—GPCR downstream signaling—POMC—multiple sclerosis	1.62e-05	0.000471	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—RRM1—multiple sclerosis	1.61e-05	0.000469	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—PTGER4—multiple sclerosis	1.61e-05	0.000468	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—CYP27B1—multiple sclerosis	1.6e-05	0.000467	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—CYP24A1—multiple sclerosis	1.6e-05	0.000467	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—CNR1—multiple sclerosis	1.59e-05	0.000463	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—PGR—multiple sclerosis	1.58e-05	0.000461	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CXCR3—multiple sclerosis	1.55e-05	0.000452	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—CCL5—multiple sclerosis	1.54e-05	0.00045	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CD28—multiple sclerosis	1.54e-05	0.000448	CbGpPWpGaD
Fentanyl—OPRM1—GPCR downstream signaling—CCR5—multiple sclerosis	1.53e-05	0.000447	CbGpPWpGaD
Fentanyl—OPRM1—GPCR downstream signaling—IL2RA—multiple sclerosis	1.51e-05	0.00044	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CCR2—multiple sclerosis	1.51e-05	0.00044	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—POMC—multiple sclerosis	1.47e-05	0.000428	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—GPC5—multiple sclerosis	1.47e-05	0.000427	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—CCL2—multiple sclerosis	1.44e-05	0.000419	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—CXCL10—multiple sclerosis	1.43e-05	0.000417	CbGpPWpGaD
Fentanyl—OPRK1—GPCR downstream signaling—POMC—multiple sclerosis	1.42e-05	0.000413	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CCL3—multiple sclerosis	1.41e-05	0.000411	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—SRM—multiple sclerosis	1.4e-05	0.000409	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CNR1—multiple sclerosis	1.39e-05	0.000406	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—CCR5—multiple sclerosis	1.39e-05	0.000406	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—IL2RA—multiple sclerosis	1.37e-05	0.0004	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—PTGER4—multiple sclerosis	1.36e-05	0.000396	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—PGR—multiple sclerosis	1.34e-05	0.00039	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CXCR3—multiple sclerosis	1.31e-05	0.000382	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—TYK2—multiple sclerosis	1.3e-05	0.00038	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CD28—multiple sclerosis	1.3e-05	0.000379	CbGpPWpGaD
Fentanyl—CYP3A4—Biological oxidations—POMC—multiple sclerosis	1.3e-05	0.000379	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—POMC—multiple sclerosis	1.29e-05	0.000375	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—BCHE—multiple sclerosis	1.28e-05	0.000373	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CCR2—multiple sclerosis	1.28e-05	0.000372	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—CCL2—multiple sclerosis	1.26e-05	0.000367	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CXCL10—multiple sclerosis	1.25e-05	0.000366	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—CD86—multiple sclerosis	1.25e-05	0.000365	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—CCL5—multiple sclerosis	1.23e-05	0.000359	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—RRM1—multiple sclerosis	1.21e-05	0.000354	CbGpPWpGaD
Fentanyl—OPRM1—GPCR downstream signaling—POMC—multiple sclerosis	1.2e-05	0.000349	CbGpPWpGaD
Fentanyl—OPRD1—GPCR downstream signaling—IL2—multiple sclerosis	1.19e-05	0.000348	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CNR1—multiple sclerosis	1.18e-05	0.000343	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—TYK2—multiple sclerosis	1.14e-05	0.000333	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—SPP1—multiple sclerosis	1.14e-05	0.000333	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	1.12e-05	0.000327	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	1.12e-05	0.000326	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—CCR5—multiple sclerosis	1.11e-05	0.000323	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CD86—multiple sclerosis	1.1e-05	0.00032	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	1.1e-05	0.00032	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—IL2RA—multiple sclerosis	1.09e-05	0.000319	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—POMC—multiple sclerosis	1.09e-05	0.000317	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—IL2—multiple sclerosis	1.08e-05	0.000316	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CCL5—multiple sclerosis	1.08e-05	0.000315	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—CCL2—multiple sclerosis	1.06e-05	0.00031	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CXCL10—multiple sclerosis	1.06e-05	0.000309	CbGpPWpGaD
Fentanyl—OPRK1—GPCR downstream signaling—IL2—multiple sclerosis	1.05e-05	0.000305	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	1.04e-05	0.000304	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—APOE—multiple sclerosis	1.01e-05	0.000294	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—SPP1—multiple sclerosis	1e-05	0.000292	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	9.87e-06	0.000288	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	9.87e-06	0.000288	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CCR5—multiple sclerosis	9.73e-06	0.000284	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—TYK2—multiple sclerosis	9.66e-06	0.000282	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—IL2RA—multiple sclerosis	9.59e-06	0.00028	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—IL2—multiple sclerosis	9.51e-06	0.000277	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CD86—multiple sclerosis	9.27e-06	0.00027	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—BCHE—multiple sclerosis	9.24e-06	0.00027	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CCL5—multiple sclerosis	9.12e-06	0.000266	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—CD80—multiple sclerosis	9.12e-06	0.000266	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—GPC5—multiple sclerosis	9.03e-06	0.000263	CbGpPWpGaD
Fentanyl—OPRM1—GPCR downstream signaling—IL2—multiple sclerosis	8.85e-06	0.000258	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—APOE—multiple sclerosis	8.85e-06	0.000258	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—POMC—multiple sclerosis	8.67e-06	0.000253	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—CCL2—multiple sclerosis	8.48e-06	0.000247	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—SPP1—multiple sclerosis	8.45e-06	0.000246	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—MAPK1—multiple sclerosis	8.3e-06	0.000242	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CCR5—multiple sclerosis	8.22e-06	0.00024	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—IL2RA—multiple sclerosis	8.1e-06	0.000236	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—IL2—multiple sclerosis	8.04e-06	0.000234	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CD80—multiple sclerosis	8e-06	0.000233	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—TYK2—multiple sclerosis	7.7e-06	0.000225	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—APOE—multiple sclerosis	7.69e-06	0.000224	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—POMC—multiple sclerosis	7.6e-06	0.000222	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—RRM1—multiple sclerosis	7.48e-06	0.000218	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—APOE—multiple sclerosis	7.48e-06	0.000218	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CCL2—multiple sclerosis	7.44e-06	0.000217	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—MAPK1—multiple sclerosis	7.28e-06	0.000212	CbGpPWpGaD
Fentanyl—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	7.02e-06	0.000205	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—BCHE—multiple sclerosis	6.97e-06	0.000203	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CD80—multiple sclerosis	6.76e-06	0.000197	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—TYK2—multiple sclerosis	6.75e-06	0.000197	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—POMC—multiple sclerosis	6.61e-06	0.000193	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—POMC—multiple sclerosis	6.42e-06	0.000187	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—IL2—multiple sclerosis	6.41e-06	0.000187	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—IL6—multiple sclerosis	6.38e-06	0.000186	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CCL2—multiple sclerosis	6.29e-06	0.000183	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—MAPK1—multiple sclerosis	6.15e-06	0.000179	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—MMP9—multiple sclerosis	6.07e-06	0.000177	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—ALB—multiple sclerosis	6.02e-06	0.000176	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—TYK2—multiple sclerosis	5.71e-06	0.000166	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—IL2—multiple sclerosis	5.62e-06	0.000164	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—IL6—multiple sclerosis	5.59e-06	0.000163	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—APOE—multiple sclerosis	5.56e-06	0.000162	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—STAT3—multiple sclerosis	5.39e-06	0.000157	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—MMP9—multiple sclerosis	5.32e-06	0.000155	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—MYC—multiple sclerosis	5.01e-06	0.000146	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—TGFB1—multiple sclerosis	5e-06	0.000146	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—MAPK1—multiple sclerosis	4.9e-06	0.000143	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—POMC—multiple sclerosis	4.78e-06	0.000139	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—IL2—multiple sclerosis	4.75e-06	0.000138	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—STAT3—multiple sclerosis	4.73e-06	0.000138	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—IL6—multiple sclerosis	4.73e-06	0.000138	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—MMP9—multiple sclerosis	4.5e-06	0.000131	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—MYC—multiple sclerosis	4.39e-06	0.000128	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—TGFB1—multiple sclerosis	4.38e-06	0.000128	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—ALB—multiple sclerosis	4.36e-06	0.000127	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—MAPK1—multiple sclerosis	4.3e-06	0.000125	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—BCHE—multiple sclerosis	4.3e-06	0.000125	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—APOE—multiple sclerosis	4.2e-06	0.000122	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—STAT3—multiple sclerosis	4e-06	0.000117	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—IL6—multiple sclerosis	3.77e-06	0.00011	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—MYC—multiple sclerosis	3.71e-06	0.000108	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—TGFB1—multiple sclerosis	3.7e-06	0.000108	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—MAPK1—multiple sclerosis	3.63e-06	0.000106	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—POMC—multiple sclerosis	3.6e-06	0.000105	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—IL6—multiple sclerosis	3.3e-06	9.63e-05	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—ALB—multiple sclerosis	3.29e-06	9.58e-05	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—IL6—multiple sclerosis	2.79e-06	8.14e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—APOE—multiple sclerosis	2.59e-06	7.54e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—POMC—multiple sclerosis	2.22e-06	6.48e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—ALB—multiple sclerosis	2.02e-06	5.9e-05	CbGpPWpGaD
